At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Post-Mkt 02-25 16:27:58 EST
18.22
+0.02
+0.11%
盘后18.20
-0.02-0.09%
16:27 EST
High19.00Low17.96Vol1.34M
Open18.10D1 Closing18.20Amplitude5.71%
Mkt Cap1.30BTradable Cap736.37MTotal Shares71.37M
T/O24.55MT/O Rate3.33%Tradable Shares40.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MoonLake posts FY 2025 interest expense of USD 7.2 million
Reuters  ·  02-25 19:13
MoonLake posts FY 2025 interest expense of USD 7.2 million
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
TIPRANKS  ·  02-24 20:54
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
MoonLake Immunotherapeutics : Leerink Partners Raises Target Price to $24 From $20
THOMSON REUTERS  ·  02-24 20:05
MoonLake Immunotherapeutics : Leerink Partners Raises Target Price to $24 From $20
MoonLake Immunotherap Is Maintained at Buy by Needham
Dow Jones  ·  02-24 18:05
MoonLake Immunotherap Is Maintained at Buy by Needham
Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept
MT Newswires Live  ·  02-24 03:58
Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and PROCEPT BioRobotics (PRCT)
TIPRANKS  ·  02-24 02:30
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and PROCEPT BioRobotics (PRCT)
BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase
Reuters  ·  02-23 22:10
BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase
BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo Nordisk
Reuters  ·  02-23 21:21
BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo Nordisk
MoonLake Immunotherapeutics - Remaining Tranches Provide up to $400 Mln Future Funding - SEC Filing
THOMSON REUTERS  ·  02-23 19:05
MoonLake Immunotherapeutics - Remaining Tranches Provide up to $400 Mln Future Funding - SEC Filing
MoonLake Immunotherapeutics - Enters First Amendment to Loan and Security Agreement - SEC Filing
THOMSON REUTERS  ·  02-23 19:05
MoonLake Immunotherapeutics - Enters First Amendment to Loan and Security Agreement - SEC Filing
MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study
MT Newswires Live  ·  02-23 16:56
MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study
MoonLake announces results from Phase 2 trial of Sonelokimab
TIPRANKS  ·  02-23
MoonLake announces results from Phase 2 trial of Sonelokimab
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Guardant Health (GH) and Bicara Therapeutics Inc. (BCAX)
TIPRANKS  ·  02-23
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Guardant Health (GH) and Bicara Therapeutics Inc. (BCAX)
MoonLake Q4 R&D expense USD 56 million, down 7.6%
Reuters  ·  02-23
MoonLake Q4 R&D expense USD 56 million, down 7.6%
MoonLake Immunotherapeutics Confirms Investor Day Webcast Schedule With Open Q&A Session
Reuters  ·  02-23
MoonLake Immunotherapeutics Confirms Investor Day Webcast Schedule With Open Q&A Session
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
GlobeNewswire  ·  02-23
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
MoonLake Immunotherap Is Maintained at Sector Perform by RBC Capital
Dow Jones  ·  02-20
MoonLake Immunotherap Is Maintained at Sector Perform by RBC Capital
RBC Raises Price Target on MoonLake Immunotherapeutics to $12 From $10, Keeps Sector Perform, Speculative Risk
MT Newswires Live  ·  02-20
RBC Raises Price Target on MoonLake Immunotherapeutics to $12 From $10, Keeps Sector Perform, Speculative Risk
MoonLake Immunotherapeutics (MLTX) Gets a Hold from RBC Capital
TIPRANKS  ·  02-20
MoonLake Immunotherapeutics (MLTX) Gets a Hold from RBC Capital
Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Dow Jones  ·  02-10
Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--